| Objective⑴To evaluate the value of HE4, CA125, CA72-4, CA153, CA19-9, CYFRA21-1,TSH and its’ combination detection in clinical diagnosis of gynecologic tumor.⑵To study the expression level of Toll-like receptor’s adaptor protein SARM,MyD88, TRIF in tissue of gynecological tumor, which provide new ideas forfurther study of the relationship between TLR signaling pathway and tumordevelopment.Materials and methodsSource of specimen114serums of gynecological cancer patients were collected in the First AffiliatedHospital of Anhui Medical University from March1,2009to May10,2011.40serums of healthy women were from the hospital health examination center.According to the needs of data analysis we divided patients into different groups indifferent ways:①the patients were divided into six groups according to pathologicaldiagnosis;②the patients were divided into three groups according to whether tumorwas malignant or not;③the patients were divided into two groups depending onwhether cases was health or not;36cases of pathological specimens of gynecologicalcancer patients were collected in the First Affiliated Hospital of Anhui MedicalUniversity from January1,2010to December30,2011. MethodsSerum HE4was detected by enzyme linked immnosorbent assay (ELISA) whileserum CA125, CA72-4, CA153, CA19-9, CYFRA21-1, TSH, TNF-α and IL-1β wasdetected by electrochemiluminescence assay and the expression level of SARM,MyD88, TRIF was detected by immunohistochemistry.ResultsHE4has a significant differences among six groups, χ~2=23.087, the positiverates of HE4in patient with gynecological adenocarcinoma, squamous cell carcinoma,other malignancies and inflammatory response were44.8%,30%,43.7%,56.5%respectively, significantly higher in the normal control group (P<0.05). HE4has asignificant differences among malignant, the benign disease and normal control, χ~2=18.020, the positive rates of HE4in patient with malignant, the benign disease were40%,42.9%respectively, significantly higher than the normal control group (P<0.05).There was significant differences between the disease group and normal control,χ~2=25.371, the positive rates of HE4in patient with disease was50%, significantlyhigher than normal controls (P<0.05); CA125has a significant differences among sixgroups, χ~2=24.141, the positive rates of CA125in patient with in adenocarcinomawas44.8%, significantly higher than those in smooth muscle tumor, othermalignancies, squamous cell carcinoma and normal control (P <0.05) the positiverates of CA125in patient with inflammation reaction was39.1%, significantly higherthan those in normal control (P<0.05). CA125has a significant differences amongmalignant, the benign disease and normal control, χ~2=8.684, the positive rates ofCA125in patient with malignant, benign disease were40%,42.9%respectively,significantly higher than those in normal control (P<0.05). There was significantdifferences between the disease and normal control, χ~2=8.662, the positive rates ofCA125in patient with disease was27.2%, significantly higher than normal control(P<0.05); CYFRA21-1has a significant differences among six groups, χ~2=14.924, thepositive rates of CYFRA21-1in patient with adenocarcinoma was34.5%, significantly higher than those in inflammatory response and normal control (P<0.05).CYFRA21-1has a significant differences among malignant, the benign disease andnormal control, χ2=11.320, the positive rates of CYFRA21-1in patient withmalignant was26.2%, significantly higher than those in benign disease and normalcontrol (P<0.05). There was significant difference between the disease and normalcontrol, χ2=4.198, the positive rates of CYFRA21-1in patient with disease was18.4%, significantly higher than normal control (P<0.05); TNF-α has a significantdifferences among six groups, F=2.752, the concentration of TNF-α in patient withadenocarcinoma was22.34.9, significantly higher than those in leiomyoma andnormal control (P<0.05), the concentration of TNF-α in patient with squamous cellcarcinoma was20.64.2, significantly higher than those in normal control; IL-1β hasa significant differences among six groups, F=10.482, the concentration of IL-1β inpatient with squamous cell carcinoma, adenocarcinoma, leiomyoma, inflammatoryresponse and other malignancies were13.12.7,22.12.3,12.83.2,13.34.9,15.55.6respectively, significantly higher than those in normal control (P <0.05);SARM has a significant differences among squamous cell carcinoma,adenocarcinoma, leiomyoma and normal control, F=13.338, the integral opticaldensity of SARM in tissue was expressed in patient with adenocarcinoma andsquamous cell carcinoma were43.121.0,37.519.9, significantly higher than thosein leiomyoma and normal control (P<0.05); MyD88has a significant differencesamong squamous cell carcinoma, adenocarcinoma, leiomyoma and normal control,F=12.049, the integral optical density of MyD88in tissue was expressed in patientwith adenocarcinoma and squamous cell carcinoma were33.520.2,31.517.8,significantly higher than those in leiomyoma and normal control (P<0.05); TRIF has asignificant differences among squamous cell carcinoma, adenocarcinoma, leiomyomaand normal control, F=7.279, the integral optical density of TRIF in tissue wereexpressed in patient with adenocarcinoma and squamous cell carcinoma were19.9±8.2,25.7±14.3, significantly higher than those in leiomyoma and normal control(P<0.05). Conclusions⑴Combination detection of tumor markers is helpful for the clinical diagnosis ofgynecological tumors,⑵All of SARM, MyD88and TRIF showed high expression in gynecologicaladenocarcinoma and squamous cell carcinoma⑶TLR4signaling pathway perhaps palys an important role in tumor development... |
PDF Full Text Request